Showing results (2571-2580 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Investigational New Drugs|January 6, 2021
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinomaCara Kenney, Tricia Kunst, Santhana Webb, et al.
Investigational New Drugs|January 6, 2021
The E3 ligase HUWE1 mediates TGFBR2 ubiquitination and promotes gastric cancer cell proliferation, migration, and invasionYuting He, Jianming Zhou, Qinsi Wan
Investigational New Drugs|December 14, 2020
Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D cultureKatrin Manda, Dajana Juerß, Paul Fischer, et al.
Investigational New Drugs|October 18, 2020
Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II studyZhi-Qiang Wang, De-Shen Wang, Feng-Hua Wang, et al.
Investigational New Drugs|October 31, 2020
Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signalingMinan Lu, Kegong Xie, Xianzhe Lu, et al.
Investigational New Drugs|September 10, 2022
Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjectsLinlin Hu, Mingmin Cai, Wei Qian, et al.
Investigational New Drugs|January 28, 2021
System Xc-: a key regulatory target of ferroptosis in cancerMan-Ru Liu, Wen-Tao Zhu, Dong-Sheng Pei
Investigational New Drugs|January 21, 2021
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axisJorge Antonio Elias Godoy Carlos, Keli Lima, Leticia Veras Costa-Lotufo, et al.
Investigational New Drugs|March 4, 2021
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesotheliomaMarjorie G Zauderer, Evan W Alley, Johanna Bendell, et al.
Pageof 372